Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing non-small cell lung cancer (NSCLC) and the role cytokines can play in the disease, with a focus on AM0010 and NKTR-214

Ticker(s): ARMO, NKTR

Who's the expert?

Name: Dr Nash Gabrail - MD

Institution: Gabrail Cancer Center

  • Founder of Gabrail Cancer Center, focused on hematological oncology.
  • Very familiar with AM0010 and NKTR-214.
  • Published more than thirty peer-reviewed articles in reputable medical journals and is a speaker on new therapies in cancer treatment.

Interview Goal
This conversation will discuss the role of IL-2 and cytokines in NSCLC as well as the potential of 2 therapies in development. Specifically the public data for AM0010 and NKTR-214 will be discussed. 

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.